Multivariate analysis for leukemia-free survival (LFS) in patients who underwent a URD or HLA-identical sibling transplantation for AML, ALL, and CML
Factors . | Relative risk . | 95% CI . | P . |
---|---|---|---|
AML* | |||
URD vs sib (no acute GVHD) | 2.02 | 1.61-2.53 | < .001 |
URD vs sib (acute GVHD present) | 1.27 | 0.98-1.65 | .072 |
Chronic GVHD | 1.08 | 0.89-1.31 | .45 |
ALL† | |||
URD vs sib | 1.02 | 0.82-1.29 | .84 |
Acute GVHD | 1.14 | 0.92-1.42 | .23 |
Chronic GVHD | 1.12 | 0.86-1.46 | .41 |
CML‡ | |||
URD vs sib | 0.95 | 0.80-1.14 | .59 |
Acute GVHD | 1.91 | 1.64-2.22 | < .001 |
Chronic GVHD | 1.21 | 1.01-1.47 | .043 |
Factors . | Relative risk . | 95% CI . | P . |
---|---|---|---|
AML* | |||
URD vs sib (no acute GVHD) | 2.02 | 1.61-2.53 | < .001 |
URD vs sib (acute GVHD present) | 1.27 | 0.98-1.65 | .072 |
Chronic GVHD | 1.08 | 0.89-1.31 | .45 |
ALL† | |||
URD vs sib | 1.02 | 0.82-1.29 | .84 |
Acute GVHD | 1.14 | 0.92-1.42 | .23 |
Chronic GVHD | 1.12 | 0.86-1.46 | .41 |
CML‡ | |||
URD vs sib | 0.95 | 0.80-1.14 | .59 |
Acute GVHD | 1.91 | 1.64-2.22 | < .001 |
Chronic GVHD | 1.21 | 1.01-1.47 | .043 |
LFS is decreased in URD transplantations for AML without acute GVHD but is similar between URD and sib transplants for ALL and CML. RR for reference group (sib) is 1.0.
URD indicates unrelated donor; sib, HLA-identical sibling; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; GVHD, graft-versus-host disease; CI, confidence interval; WBC, white blood cell; and CR1, first complete remission.
Interaction present between donor source and aGVHD. Model also adjusted for GVHD prophylaxis, WBC count, duration of CR1, and cytogenetics and stratified by disease stage, graft type, and Karnofsky score.
Model also adjusted for patient's age and stratified by disease stage, graft type, and Karnofsky score.
Model also adjusted for patient age and time from diagnosis to transplantation, and stratified by disease stage, graft type, and Karnofsky score.